Knight Therapeutics Inc. (TSE:GUD – Get Free Report) insider Sime Armoyan sold 300,000 shares of Knight Therapeutics stock in a transaction dated Monday, September 16th. The stock was sold at an average price of C$6.13, for a total transaction of C$1,839,000.00.
Knight Therapeutics Trading Down 1.8 %
Shares of TSE:GUD traded down C$0.11 during trading on Friday, reaching C$6.02. The stock had a trading volume of 31,200 shares, compared to its average volume of 66,414. The stock has a market cap of C$609.28 million, a P/E ratio of -30.10, a PEG ratio of -1,013.50 and a beta of 0.48. The company has a quick ratio of 1.79, a current ratio of 3.41 and a debt-to-equity ratio of 7.62. Knight Therapeutics Inc. has a fifty-two week low of C$4.35 and a fifty-two week high of C$6.23. The business has a fifty day moving average price of C$5.72 and a 200-day moving average price of C$5.69.
Knight Therapeutics (TSE:GUD – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported C($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.03 by C($0.05). The business had revenue of C$95.57 million for the quarter, compared to analyst estimates of C$89.83 million. Knight Therapeutics had a negative return on equity of 2.70% and a negative net margin of 6.28%. As a group, analysts anticipate that Knight Therapeutics Inc. will post 0.1077501 earnings per share for the current fiscal year.
Analyst Ratings Changes
Check Out Our Latest Stock Report on GUD
About Knight Therapeutics
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Read More
- Five stocks we like better than Knight Therapeutics
- 5 Top Rated Dividend Stocks to Consider
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Ride Out The Recession With These Dividend Kings
- MarketBeat Week in Review – 9/16 – 9/20
- Investing in Travel Stocks Benefits
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.